Session » (1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1219

Anti-Ro52 Antibody Identifies Patients with More Severe Lung disease among Patients with Idiopathic Inflammatory Myopathy

10:30AM-12:30PM: Abstract Number: 1210

Artificial Intelligence-Based Capillaroscopy and Laboratory Biomarkers to Predict Disease Activity in Idiopathic Inflammatory Myopathies: Preliminary Data from the CapIAMI Cohort

10:30AM-12:30PM: Abstract Number: 1214

Association of Paraoxonase1 activity with Calcinosis in Patients with Scleroderma and Dermatomyositis : An exploratory analysis

10:30AM-12:30PM: Abstract Number: 1209

Beyond Muscle Strength: Functional Performance Measures Enhance Assessment of Disease Activity in Juvenile Dermatomyositis

10:30AM-12:30PM: Abstract Number: 1207

Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis

10:30AM-12:30PM: Abstract Number: 1195

Discordance between Immunoblot and ELISA in the detection of Jo-1 and Ro/Ro-52 Autoantibodies

10:30AM-12:30PM: Abstract Number: 1191

Effect of ER Stress Inhibition With 4-Phenylbutyric Acid on Disease Phenotype in a Mouse Model of Myositis

10:30AM-12:30PM: Abstract Number: 1197

Genetic Profiling of Idiopathic Inflammatory Myopathies in Indian Patients Reveals Genotype-Phenotype Correlation

10:30AM-12:30PM: Abstract Number: 1202

High Prevalence of Asymptomatic Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Validation of ACR/CHEST Risk Factors in a Hong Kong Cohort

10:30AM-12:30PM: Abstract Number: 1192

Idiopathic Inflammatory Myopathies: A Prospective Phase 4 Controlled Trial Of Recombinant Herpes Zoster Vaccine

10:30AM-12:30PM: Abstract Number: 1198

Induction of stable, GC-free remission in patients with severe, therapy-refractory anti-synthetase syndrome after using the bispecific CD19xCD3 T cell engager blinatumomab

10:30AM-12:30PM: Abstract Number: 1199

Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (SARDs): Radiologic and Histologic Correlations

10:30AM-12:30PM: Abstract Number: 1193

Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis

10:30AM-12:30PM: Abstract Number: 1216

Measurement Properties of a Shorter Health Assessment Questionnaire (HAQ-II) in Patients with Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 1200

Mortality in Idiopathic Inflammatory Myopathy in the Toulouse cohort (MIIRTALITY)

10:30AM-12:30PM: Abstract Number: 1208

Neutrophil Activation in Juvenile Dermatomyositis: Associations with Muscle Function and Disease Progression

10:30AM-12:30PM: Abstract Number: 1206

Overexpression of lymphotoxin in autophagy-deficient mice as model for inclusion body myositis

10:30AM-12:30PM: Abstract Number: 1211

Plasma Levels of miR-133a-3p and miR-1-3p as Potential Biomarkers of Muscle Involvement and Initial Treatment Response in Myositis

10:30AM-12:30PM: Abstract Number: 1220

Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases

10:30AM-12:30PM: Abstract Number: 1196

Prevalence of and Factors Associated with Chronic Opioid Use among Individuals with Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 1201

Prognostic Significance of 1-Year Pulmonary Function Changes in Myositis-Associated Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 1205

Real-time MRI for assessment of swallowing impairment in inclusion body myositis and oculopharyngeal muscular dystrophy.

10:30AM-12:30PM: Abstract Number: 1212

Relapse in Idiopathic Inflammatory Myopathies: insights from extended MyoCite and Italian Consortia

10:30AM-12:30PM: Abstract Number: 1215

Remission Rates and Predictors in Idiopathic Inflammatory Myopathy Subtypes: Insights from a Single-Center Cohort

10:30AM-12:30PM: Abstract Number: 1194

Risk of Calcinosis with Proton Pump Inhibitor Use in Adult Dermatomyositis and Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1203

Rituximab in Treatment Refractory vs Treatment Naive Anti-Signal Recognition Particle (SRP) Myositis – A Case Series

10:30AM-12:30PM: Abstract Number: 1218

Social Determinants Shape Health Outcomes in Idiopathic Inflammatory Myopathies: Insights from Lived Experience of 1,252 Patients

10:30AM-12:30PM: Abstract Number: 1213

Transitional Changes on High Resolution Computed Tomography (HRCT) in idiopathic inflammatory Myopathy- Associated Interstitial Lung Disease (IIM-ILD)

10:30AM-12:30PM: Abstract Number: 1217

Validation and clincial use of anti-MDA5 test – LIA versus ELISA

10:30AM-12:30PM: Abstract Number: 1204

Validity and reliability of a new ultrasound-based semiquantitative echogenicity grading scale for myositis.

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].